Dr. Sehgal on the Clinical Implications of CAR T-Cell Therapy in DLBCL
July 30th 2019Alison R. Sehgal, MD, assistant professor of medicine, hematologist/medical oncologist, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses the clinical implications of CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL).
Read More
Dr. Sehgal on Managing CRS and Neurotoxicity From CAR T-Cell Therapy
July 9th 2019Alison R. Sehgal, MD, assistant professor of medicine, hematologist/medical oncologist, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses ways to manage cytokine release syndrome (CRS) and neurotoxicity associated with CAR T-cell therapy.
Read More